Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Erlotinib appears to produce prolonged remission of insulin-requiring type 2 diabetes associated with metabolic syndrome and chronic kidney disease
Marvin B. Brooks
The British Journal of Diabetes (2012) Vol. 12, Iss. 2, pp. 87-90
Closed Access | Times Cited: 12

Showing 12 citing articles:

Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?
Athanasios Fountas, Leonidas Nikolaos Diamantopoulos, Agathocles Tsatsoulis
Trends in Endocrinology and Metabolism (2015) Vol. 26, Iss. 11, pp. 643-656
Closed Access | Times Cited: 88
Neratinib protects pancreatic beta cells in diabetes
Amin Ardestani, Sijia Li, Karthika Annamalai, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 56
Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia
Brittany M. Duggan, Kevin P. Foley, Brandyn D. Henriksbo, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 37
Epidermal Growth Factor Receptor: A Potential Therapeutic Target for Diabetic Kidney Disease
Lili Sheng, George Bayliss, Shougang Zhuang
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 26
Antidiabetic Effects of the Senolytic Agent Dasatinib
Omid Salaami, Chia‐Ling Kuo, Matthew T. Drake, et al.
Mayo Clinic Proceedings (2021) Vol. 96, Iss. 12, pp. 3021-3029
Open Access | Times Cited: 19
Erlotinib and Gefitinib, Epidermal Growth Factor Receptor Kinase Inhibitors, May Treat Non-Cancer-Related Tumor Necrosis Factor-α Mediated Inflammatory Diseases
Marvin B. Brooks
The Oncologist (2013) Vol. 18, Iss. 1, pp. e3-e5
Open Access | Times Cited: 16
Neratinib is an MST1 inhibitor and restores pancreatic β-cells in diabetes
Amin Ardestani, Matthew S. Tremblay, Weijun Shen, et al.
Cell Death Discovery (2019) Vol. 5, Iss. 1
Open Access | Times Cited: 14
Case Report: Neratinib Therapy Improves Glycemic Control in a Patient With Type 2 Diabetes and Breast Cancer
Vasileios Angelis, Stephen R.D. Johnston, Amin Ardestani, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 8
Kinase inhibitors for cancer alter metabolism, blood glucose, and insulin
Brittany M. Duggan, Daniel M. Marko, Raveen Muzaffar, et al.
Journal of Endocrinology (2022)
Open Access | Times Cited: 7
Literature review: drug and alcohol-induced hypoglycaemia
Tejas Kalaria, Ye Lynn Ko, Kiran Kumar Jimmy Issuree
Journal of Laboratory and Precision Medicine (2021) Vol. 6, pp. 21-21
Open Access | Times Cited: 7
Erlotinib and gefitinib, small-molecule EGFR inhibitors. New uses for old drugs?
Marvin B. Brooks
The British Journal of Diabetes (2012) Vol. 12, Iss. 4, pp. 195-196
Closed Access | Times Cited: 4
Targeting the epidermal growth factor receptor (EGFR/ErbB) for the potential treatment of renal pathologies
Mohamed Tawengi, Yazan Al-Dali, Abdelaziz M. Tawengi, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Page 1

Scroll to top